GSK (LON:GSK) Hits New 52-Week Low – Time to Sell?

GSK plc (LON:GSK)’s stock price hit a new 52-week low on Wednesday . The company traded as low as GBX 1,368 ($17.81) and last traded at GBX 1,371.89 ($17.86), with a volume of 2147000000 shares changing hands. The stock had previously closed at GBX 1,391.50 ($18.11).

Analyst Upgrades and Downgrades

GSK has been the topic of a number of recent research reports. Shore Capital reissued a “buy” rating on shares of GSK in a report on Wednesday, August 28th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,850 ($24.08) target price on shares of GSK in a research report on Tuesday, September 3rd. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 1,820 ($23.69) price target on shares of GSK in a report on Tuesday, September 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average price target of GBX 1,842.50 ($23.98).

GSK Price Performance

The company has a market capitalization of £55.92 billion, a price-to-earnings ratio of 1,212.83, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The business has a fifty day moving average price of GBX 1,528.84 and a 200 day moving average price of GBX 1,588.89. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.

GSK Announces Dividend

The business also recently announced a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be paid a dividend of GBX 15 ($0.20) per share. The ex-dividend date is Thursday, November 14th. This represents a yield of 1.03%. GSK’s payout ratio is 5,309.73%.

Insiders Place Their Bets

In other news, insider Jonathan Symonds bought 7,150 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average cost of GBX 1,394 ($18.15) per share, for a total transaction of £99,671 ($129,746.16). In other news, insider Elizabeth (Liz) McKee Anderson bought 446 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The stock was acquired at an average price of GBX 2,051 ($26.70) per share, with a total value of £9,147.46 ($11,907.65). Also, insider Jonathan Symonds acquired 7,150 shares of GSK stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of GBX 1,394 ($18.15) per share, with a total value of £99,671 ($129,746.16). In the last three months, insiders have purchased 7,604 shares of company stock worth $10,893,886. 1.61% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.